Walder Wyss advised Sulzer in the acquisition of Haselmeier Group

Sulzer has agreed to acquire the Swiss-German Haselmeier Group for EUR 100 million. Closing of the transaction is planned for the fourth quarter of 2020.

Haselmeier is a leading provider of patented injection systems such as subcutaneous self-injection pens for use in fast growing indications such as reproductive health, growth disorders, osteoporosis and diabetes.

With the acquisition of Haselmeier, Sulzer will complement its healthcare portfolio and leverage its APS expertise in precision injection molding to seize growth opportunities in the fast-growing drug delivery devices market.

The team

Walder Wyss (lead counsel) has advised Sulzer together with the German law firm Gleiss Lutz and further foreign law firms. The Walder Wyss team was led by Markus Vischer (Partner, Corporate/M&A), Claudia Weber (Senior Associate, Corporate/M&A) and Nico Bernhard (Associate, Corporate/M&A) and further included Dimitrios Berger (Associate, Corporate/M&A),Christine Schweikard (Associate, IP/IT) and Jasmin Eicher (Junior Associate, Corporate/M&A).